Monoclonal antibodies targeting PD-1 or PD-L1 have shown remarkable clinical efficacy across multiple cancer types, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and bladder cancer (27, 28). Here, CD274 is linked to non-small cell lung carcinoma.